Atorvastatin Pfizer 40 mg film coated tablets Ireland - English - HPRA (Health Products Regulatory Authority)

atorvastatin pfizer 40 mg film coated tablets

pfizer ireland pharmaceuticals - atorvastatin calcium - film-coated tablet - 40 milligram(s) - hmg coa reductase inhibitors; atorvastatin

EXEMESTANE PFIZER Australia - English - Department of Health (Therapeutic Goods Administration)

exemestane pfizer

pfizer australia pty ltd - exemestane -

Amlodipine Pfizer Australia - English - Department of Health (Therapeutic Goods Administration)

amlodipine pfizer

pfizer australia pty ltd - amlodipine -

Atorvastatin Pfizer Australia - English - Department of Health (Therapeutic Goods Administration)

atorvastatin pfizer

pfizer australia pty ltd - atorvastatin calcium -

Gabapentin Pfizer Australia - English - Department of Health (Therapeutic Goods Administration)

gabapentin pfizer

pfizer australia pty ltd - gabapentin -

Latanoprost Pfizer Australia - English - Department of Health (Therapeutic Goods Administration)

latanoprost pfizer

pfizer australia pty ltd - latanoprost -

Paracetamol IV Pfizer Australia - English - Department of Health (Therapeutic Goods Administration)

paracetamol iv pfizer

pfizer australia pty ltd - paracetamol -

Quinapril Pfizer Australia - English - Department of Health (Therapeutic Goods Administration)

quinapril pfizer

pfizer australia pty ltd - quinapril hydrochloride -

Sertraline Pfizer Australia - English - Department of Health (Therapeutic Goods Administration)

sertraline pfizer

pfizer australia pty ltd - sertraline hydrochloride -

Exemestane Pfizer New Zealand - English - Medsafe (Medicines Safety Authority)

exemestane pfizer

pfizer new zealand limited - exemestane 25mg - coated tablet - 25 mg - active: exemestane 25mg excipient: crospovidone hydrated silica hypromellose   macrogol 6000 magnesium carbonate magnesium stearate mannitol methyl hydroxybenzoate polysorbate 80 polyvinyl alcohol powdered cellulose simeticone sodium starch glycolate sucrose   titanium dioxide - · the adjuvant treatment of postmenopausal women with oestrogen receptor positive or receptor unknown early breast cancer after initial adjuvant tamoxifen to reduce the risk of recurrence (distant and loco-regional) and contralateral breast cancer · the treatment of advanced breast cancer in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy · the third-line hormonal treatment of advanced breast cancer in women with natural or induced postmenopausal status whose disease progressed following treatment with anti-oestrogens and either non-steroidal aromatase inhibitors or progestins.